Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune tolerance CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company ...

This repository provides unofficial binary wheels for Pygame for Python on Windows. The files are unofficial (meaning: informal, unrecognized, personal, unsupported, no warranty, no liability, ...

Coursera shares dropped over 10%, despite strong Q3 results and raised full-year revenue guidance, highlighting investor skepticism. COUR's value is compelling at current prices, trading at just 11.8x ...

Ladies and gentlemen, thank you for standing by, and welcome to Coursera's Third Quarter 2025 Earnings Call. [Operator Instructions] And this call is being recorded. [Operator Instructions] I would ...

Coursera, Inc. (NYSE:COUR) posted better-than-expected second-quarter results after Thursday’s closing bell. Coursera reported quarterly earnings of 12 cents per share, which beat the analyst ...

Coursera, Inc. (NYSE:COUR) shares are rallying after the company released its second-quarter results after Thursday's closing bell. Here's a look at the details from the report. Check out the current ...

The Nashville Public Education Foundation has announced that Katie Cour will step down from her role as president and chief executive officer, effective July 3, after a seven-year run. According to a ...

Kanishma Ray is a writer at GameRant, who's known to play a mean violin (decently, that is). She's a Computer Science student by day and a wordsmith by night, with a knack for crafting engaging and ...

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise. It took COUR Pharmaceuticals a full decade before ...

Shares of online learning platform Coursera (NYSE:COUR) fell 12.7% in the afternoon session after the company reported underwhelming fourth quarter results. Its revenue and EBITDA guidance for the ...

Ewan has been a content writer since 2020, and loves nothing more than discussing all things gaming. While he's been playing games all his life, he has a particular interesting in anything even ...

CNP-104 is a biodegradable nanoparticle that previously received fast track designation from FDA in January 2022, which would eventually make it eligible for accelerated approval and priority review.